UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Amendment No. 25)
Solicitation/Recommendation Statement
under Section 14(d)(4) of the
Securities Exchange Act of 1934
Complete Genomics, Inc.
(Name of Subject Company)
Complete Genomics, Inc.
(Names of Person(s) Filing Statement)
Common Stock, $0.001 par value
per share
(Title of Class of Securities)
20454K104
(CUSIP Number of Class of Securities)
A. W. Homan
Senior Vice President, General Counsel and Secretary
Complete Genomics, Inc.
2071 Stierlin Court
Mountain View, California 94043
(650) 943-2800
(Name, address and telephone numbers of person authorized to receive notices and communications on behalf of the persons filing statement)
with copies to:
Alan C. Mendelson
Latham & Watkins LLP
140 Scott Drive
Menlo Park, CA 94025
(650) 328-4600
¨
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
This Amendment No. 25 (the
Amendment
) amends and supplements the
Solicitation/Recommendation Statement on Schedule 14D-9 of Complete Genomics, Inc. (
Complete
or the
Company
) filed with the Securities and Exchange Commission (the
SEC
) on September 25,
2012 and amended on September 27, 2012, October 2, 2012, October 5, 2012, October 22, 2012, November 2, 2012, November 13, 2012, November 15, 2012, November 20,
2012, November 26, 2012, November 27, 2012, November 28, 2012, December 7, 2012, December 13, 2012, December 17, 2012, December 28, 2012, January 7,
2013, January 11, 2013, January 18, 2013, January 25, 2013, February 1, 2013, February 6, 2013, February 22, 2013 and February 26, 2013 (as amended, the
Schedule
14D-9
). The Schedule 14D-9 relates to the tender offer by Beta Acquisition Corporation, a Delaware corporation (
Purchaser
) and a wholly owned subsidiary of BGI-Shenzhen, a company organized under the laws of the
Peoples Republic of China (
Parent
or
BGI
), to purchase all of the outstanding common stock, par value $0.001 per share, of Complete (the
Shares
), at a price of $3.15 per Share, net to
seller in cash, without interest and less any applicable withholding taxes, upon the terms and conditions set forth in the Offer to Purchase dated September 25, 2012 (the
Offer to Purchase
) and the related Letter of
Transmittal (which, together with the Offer to Purchase, as each may be amended or supplemented from time to time, constitute the
Offer
). The Offer is described in a Tender Offer Statement on Schedule TO filed by Parent and
Purchaser with the SEC on September 25, 2012. The Offer to Purchase and the Letter of Transmittal were filed with the Schedule 14D-9 as Exhibits (a)(1)(A) and (a)(1)(B), respectively.
Except as otherwise set forth below, the information set forth in the Schedule 14D-9 remains unchanged and is incorporated by reference
as relevant to the items in this Amendment. Capitalized terms used and not defined herein shall have the meanings assigned to such terms in the Schedule 14D-9. This Amendment is being filed to reflect certain updates as reflected below.
Item 8.
|
Additional Information.
|
Item 8 of the Schedule 14D-9 is hereby amended and supplemented to add to the end of the Section entitled Extension of the Offer the following:
On March 3, 2013, Parent and Purchaser announced an extension of the expiration date of the Offer until 11:59 p.m., New York City
time, on Thursday, March 14, 2013. Computershare Trust Company, N.A., the depositary for the Offer, has indicated that, as of the close of business on March 1, 2013, approximately 30,715,625 Shares, or 87% of the outstanding Shares, have been
validly tendered in and not withdrawn from the Offer, including Shares subject to guaranteed delivery procedures.
The press
release announcing the extension of the Offer is attached hereto as Exhibit (a)(2)(U) and is incorporated herein by reference.
Item 9 of the Schedule 14D-9 is hereby amended and supplemented to add the following exhibit:
|
|
|
Exhibit
Number
|
|
Description
|
(a)(2)(U)
|
|
Press Release issued by BGI-Shenzhen on March 3, 2013 (incorporated herein by reference to Exhibit (a)(5)(BB) to the Schedule TO-T/A of BGI-Shenzhen and Beta Acquisition
Corporation, filed with the SEC on March 4, 2013).
|
2
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
|
|
|
COMPLETE GENOMICS, INC.
|
|
|
By:
|
|
/s/ A. W. Homan
|
Name:
|
|
A. W. Homan
|
Title:
|
|
Senior Vice President, General Counsel and Secretary
|
Dated: March 4, 2013
3
Global X Genomics and Bi... (NASDAQ:GNOM)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Global X Genomics and Bi... (NASDAQ:GNOM)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024